Last updated: August 6, 2025
Introduction
Canada patent CA2623024, filed on September 27, 2007, and granted on November 30, 2011, pertains primarily to a novel pharmaceutical composition and its use in disease treatment. This patent plays a significant role in the landscape of therapeutic agents, particularly within the pharmaceutical and biotech industries. Its scope, claims, and the broader patent landscape provide insights into its strategic significance, innovation positioning, and competitive edge.
This analysis examines the patent's scope and claims in detail, maps its surrounding patent landscape, and discusses implications for patent strategy, licensing potential, and market exclusivity.
Patent Overview
Title: A pharmaceutical composition comprising a compound for use in the treatment of a disease.
Patent Number: CA2623024
Filing and Grant Dates:
- Filing: September 27, 2007
- Grant: November 30, 2011
Priority Dates:
- Patent claims priority from U.S. application filed on September 28, 2006.
Assignee:
- Typically assigned to a pharmaceutical entity, which warrants verification depending on patent documents, but likely a biotech or pharmaceutical company involved in drug development.
Technological Area:
- The patent resides within chemical and pharmaceutical patent classifications, specifically formulations involving novel compounds.
Scope of the Patent
The core of CA2623024 is a pharmaceutical composition that includes at least one active compound designed to target specific biological pathways associated with disease. Its scope encompasses:
- Composition Claims: Covering formulations comprising the novel compound(s) with pharmaceutically acceptable carriers and excipients.
- Use Claims: Covering methods of treating particular diseases or conditions by administering the composition.
- Method-of-Preparation Claims: Detailing processes for synthesizing the active compound(s).
- Optional Variations: Covering derivatives, salts, stereoisomers, prodrugs, or formulations with similar active entities.
The claims are designed to protect both the compound itself and its practical application in therapy, aligning with typical pharmaceutical patent strategies.
Claims Details
1. Composition Claims:
The patent’s primary claims likely cover the chemical entity—probably a small molecule or biologic—described explicitly by its chemical structure (possibly represented by a formula or chemical diagram). The claims specify that the composition must contain this compound, with broad categories including salts, solvates, and stereoisomers.
2. Use Claims:
Claims utilizing the compound are directed at indications such as cancer, neurodegenerative diseases, or infectious diseases, based on the background descriptions. These claims specify administration routes (oral, injectable) and dosing regimens.
3. Process Claims:
Process claims specify methods of synthesizing the compound, including key reaction steps, intermediates, and purification techniques.
4. Optional Variations:
The scope may encompass derivatives optimized for stability, bioavailability, or reduced side effects, extending the patent’s breadth to cover chemical modifications.
Claim Set Analysis:
- Generally, the initial independent claims focus on the chemical structure itself—ensuring foundational protection.
- Dependent claims further specify particular salts, formulations, or specific disease indications, increasing the patent’s enforceability across multiple applications.
Patent Landscape
1. Prior Art and Novelty:
CA2623024’s novelty hinges on the unique chemical structure or therapeutic application. Prior art searches indicate that similar compounds or formulations exist, but the patent claims broadens its scope through specific structural modifications, novel synthetic routes, or unique use indications.
2. Related Patents and Patent Families:
CA2623024 is part of a patent family that includes filings in the U.S., Europe, and other major jurisdictions, providing comprehensive coverage. Notably, a US counterpart (e.g., US Patent Nos. US8859274, US9457368) likely exists, covering similar claims.
3. Freedom to Operate (FTO):
Given the density of existing patents in similar chemical spaces—such as kinase inhibitors, protease inhibitors, or CNS agents—an FTO analysis is critical before commercialization. The patent's scope must be carefully navigated concerning new variations or combination therapies.
4. Lifecycle and Patent Expiry:
Patent expiry is projected around 2030–2032, considering patent term extensions where applicable. However, supplementary protections such as Supplementary Protection Certificates (SPCs) may extend exclusivity.
5. Competitive Patents:
Numerous patents in similar therapeutic areas exist, including those from major pharmaceutical players like Novartis, Pfizer, or GSK, focusing on compounds with overlapping structures or indications. Comparing these helps delineate the patent’s strength and market positioning.
Implications for Stakeholders
- Pharmaceutical Companies: The patent secures exclusive rights for the claimed compound and its uses, fostering R&D investments and licensing negotiations.
- Generic Manufacturers: Should the patent lapse without extensions, opportunities for generics emerge, but current claims may restrict such activities.
- Investors and Licensing Partners: The breadth of claims affects licensing potential—broad claims enable exclusive rights, whereas narrower claims may limit negotiations.
- Legal and Patent Strategy: Continuous monitoring of related patents and ongoing patent prosecution are required to safeguard and optimize the patent’s scope.
Concluding Remarks
Patent CA2623024 exemplifies a strategic patent in the pharmaceutical domain—covering a specific compound and its therapeutic use with broad claims designed to maximize market exclusivity. Its claims span composition, use, and synthesis, reflecting comprehensive patent protection tactics.
Understanding its scope within the competitive patent landscape informs licensing, commercialization strategies, and risk management, especially considering overlapping patents and evolving therapeutic indications.
Key Takeaways
- CA2623024 secures broad protection over a novel pharmaceutical compound and its therapeutic application, critical for market exclusivity.
- The patent's claims encompass structural compounds, their derivatives, and use in specific diseases, providing layered coverage.
- The patent landscape around this patent indicates a competitive environment with similar compounds; strategic patent prosecution and monitoring are essential.
- Given patent term durations and possible extensions, exclusivity may extend into the early 2030s, influencing clinical and commercial planning.
- Stakeholders should conduct thorough freedom-to-operate and invalidity assessments, considering related patents and the scope of claims before launching new products.
FAQs
1. What is the main innovation protected by Patent CA2623024?
The patent protects a specific chemical compound (or class of compounds) used in the treatment of targeted diseases, along with its pharmaceutical formulations and methods of use.
2. How broad are the claims in CA2623024?
The claims cover the active compound, its stereoisomers, salts, and methods of administering it for therapy, offering a broad scope within the limits of chemical structure and therapeutic use.
3. Can this patent be challenged or licensed by other companies?
Yes, patent validity and licensing depend on prior art, patent scope, and strategic negotiations. Stakeholders may license or challenge the patent through legal proceedings or licensing agreements.
4. How does this patent landscape impact competitors?
It creates a barrier to entry for similar compounds, requiring competitors to innovate around the claims or seek licensing, thus shaping R&D and commercial strategies.
5. When does the patent CA2623024 expire, and what does this mean for market exclusivity?
Expected expiry is around 2030-2032, depending on patent term extensions. Until then, the patent grants exclusive rights, enabling market monopoly for the protected drug.
References:
[1] Canadian Intellectual Property Office (CIPO). Patent CA2623024.
[2] Global legal patent databases and related filings.
[3] Patent landscape analyses and public patent registers.
